Objective: New antidepressant treatments are needed that are effective, rapid acting, safe,
and tolerable. Intermittent theta-burst stimulation (iTBS) is a noninvasive brain stimulation
treatment that has been approved by the US Food and Drug Administration for treatment-
resistant depression. Recent methodological advances suggest that the current iTBS
protocol might be improved through 1) treating patients with multiple sessions per day at
optimally spaced intervals, 2) applying a higher overall pulse dose of stimulation, and 3) …

Background: Intermittent theta-burst stimulation (iTBS) is an FDA-approved treatment for
treatment-resistant depression (TRD). Typical courses involve daily stimulation sessions for
six weeks and average response rates are around 50%. Several studies have demonstrated
the safety and potential enhanced efficacy of accelerated theta-burst stimulation. Higher pre-
treatment anti-correlation between the stimulated region of the left dorsolateral prefrontal
cortex (L-DLPFC) and subcallosal cingulate cortex (SCC) has been associated with better …